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Background: Connective tissue diseases (CTD) might be associated with various
malignancies, and one of the most frequent is lung cancer (LC). Despite our understanding
of pathogenesis, this association remains still unclear. The aim of the present study is to
describe the clinical characteristics of patients with CTD who developed LC.
Methods: Of 375 successive patients with CTD followed up to University Hospital between
1995 and 2004, 24 patients were diagnosed with LC: 11 (46%) had systemic sclerosis (SSc), 6
(25%) rheumatoid arthritis (RA), 6 (25%) systemic lupus erythematosus (SLE), and 1 (4%)
dermatomyositis. We analyzed LC stage, radiological presentation, histological type,
patients’ smoking status, method of diagnosis, treatment applied, and disease outcome.
Results: Average duration of CTD was 13.95 (range 0–30) years. Non-small cell lung cancer
(NSCLC) was significantly more frequent than small-cell lung cancer (SCLC). Among
patients with NSCLC, 21 patients (85%) presented with stage III or IV. With regard to
treatment, 13% patients underwent surgery, 25% chemotherapy, 4% patients combined
chemo- and radiotherapy and 58% patients had only supportive therapy. The median
survival was 5 months (range 1–96 months).
Conclusion: The majority of CTD patients who developed LC were diagnosed at advanced
stage and had poor survival. Efforts for early detection of LC in CTD patients’ group are
warranted.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Clinical features of lung cancer in patients with connective tissue diseases 621Introduction chest radiograph, computed tomography, and lung functionTable 1 Characteristics of 24 patients with lung cancer
and connective tissue disease.
Characteristics Number of patients (%)
Age (years)Although tobacco smoking is the most significant risk factor
for developing lung cancer (LC), it has been known that
other risk factors may contribute to its development. Some
of these risk factors are at least partially genetically
influenced such as granulomatous and fibromatous disease.1
Pulmonary fibrosis, either idiopathic or caused by chronic
infection, might play a role in predisposition to lung
adenocarcinoma.2 Connective tissue diseases (CTD) repre-
sent a large group of diseases which can be associated with
carcinoma of different localizations, and most frequently
with breast and lung cancers.1,3
The first case of cancer associated with CTD was
published more than 50 years ago.4 Risk factors for LC
development in CTD are still the subject of basic research.
Those factors are defined as positive antricentromere
antibody, presence of anti-tipoisomerase 1, and lung fibrosis
in patients with systemic sclerosis (SSc).5–7 Immunosuppres-
sive drugs are also a risk factor.1,8 Similarly, therapeutic
modalities, such as radiotherapy and cytotoxic drugs, seem
to carry increased risk for initiation of CTD in patients with
cancer.1,9–13
There are even studies that show higher risk for cancer
occurrence in relatives of those who suffer from SSc.14
Exposure to silica dust and solutions such as trichlorethy-
lene, benzene and other aromatic solvents carries a higher
risk for occurrence of LC in SSc.15 Tobacco smoking, the most
significant risk factor for developing LC, is especially
considered risk factor in patients with rheumatoid arthritis
(RA) and dermatomyositis (DM).16 There is higher risk for
developing LC and lymphoma in patients with RA, as well as
for developing colorectal cancer but this latter is of slightly
lower risk degree.1,17 Also, patients with systemic lupus
erythematosus (SLE) have higher incidence of cancer.1,18
The aim of this study was to describe the incidence and
the clinical characteristics of a cohort of patients with CTD
and LC hospitalized in our institution over a 10 year’s period.Mean 57.5
Median 54
Range 39–73
Sex
Male/female 1/23 (4, 96)
Smoking history
Smokers 7 (29%)
Non-smokers 10 (42%)
Ex-smokers 7 (29%)
Type of CTD
DM 1 (4)
RA 6 (25)
SLE 6 (25)
SSc 11 (46)
Limited SSc 8
Diffuse 3
Duration of CTD (years)
Mean 13.95
Median 12.5
Range 0–30
Abbreviations: CTD, connective tissue disease; DM, derma-
tomyositis; RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus; SSc, systemic sclerosis.Patients and methods
Twenty-four patients with LC and CTD treated at our
Institute for Lung Diseases and Tuberculosis during the
period 1995–2004 were retrospectively analyzed. The
purpose of this study was to determine age and sex of
patients with CTD who developed LC, to reconsider other
risk factors for its appearance and to estimate influence of
LC on a course of CTD and its outcome. We also intended to
determine frequency of particular LC histological types that
appear in patients with CTD, and to compare them to each
other in terms of method of setting LC diagnosis, stage of
the disease, chest radiograph, lung function parameters,
performance status, tobacco smoking status, applied ther-
apy and survival. Patients’ characteristics are shown in
Table 1.
The patients’ median age at presentation of LC was 54
years. Ninety-six percent (23/24) of patients were female.
Histological diagnosis of LC was made in all patients. All of
them underwent clinical evaluation (detailed history, smok-
ing status, and physical examination and performance
status), followed by complete blood counts and chemistry,tests. Initial treatment of CTD included systemic glucocorti-
coids in 21/24 patients, methotrexate in 8/24 patients, gold
salts in 4/24 patients and cyclophosphamide in 5/24
patients. Data on diagnostic procedures, histology, treat-
ment, and survival for LC were obtained by reviewing
medical records.
As a retrospective study in nature, patient consent and
the approval of Internal Review Boards are not included.Results
Average duration of CTD at diagnosis of LC was 13.95 (range
0–30) years. Non-small cell lung cancer (NSCLC) was found in
20 patients, and small cell lung cancer (SCLC) in four. One
patient (a 73-year old female with SLE) developed a
synchronous primary cancer in lung and kidney. Diagnoses
were confirmed by fiberoptic bronchoscopy in 14 patients,
by fine needle aspiration biopsy (FNAB) in seven patients,
and by pleuroscopy in three of them. Histological types and
staging of LC are shown in Table 2. Among patients with
NSCLC and known stage of the disease, according to the
American Joint Committee on Cancer (AJCC), one patient
presented with stage IB, two with stage IIA, one with stage
IIIB, and 20 (83%) with stage IV. Almost half of patients (54%)
were presented with tumour like shadow on chest X-ray,
tumour with ipsilateral effusion in 25%, atelectasis in 17%,
and pleural effusion in 4%.
In terms of performance, more than half of patients had
Karnofsky index 70–80% (Table 3). Metastatic disease was
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Table 3 Clinical findings and course of 24 patients with
connective tissue disease and lung cancer.
Characteristics Number of
patients (%)
Tumour related chest X-ray findings
Tumour like shadow 13 (54)
Atelectasis (lobar) 4 (17)
Tumour+pleural effusion 6 (25)
Pleural effusion 1 (4)
CVD related chest X-ray findings
Diffuse interstitial fibrosis 24 (100%)
Karnowsky performance status
90–100% 7 (29)
70–80% 14 (58)
50–60% 3 (13)
Metastatic disease (site)
Liver 8 (33)
CNS 2 (8)
Neck lymph nodes 6 (25)
Bones 4 (17)
Treatment of LC
Surgery 3 (13)
Chemotherapy 6 (25)
Combined chemo- and radiotherapy 1 (4)
Symptomatic 14 (58)
T.N. Adzˇic´ et al.622found in 20/24 patients. Distribution of metastases and
clinical course of patients is shown in Table 3. Chronic
obstructive pulmonary disease was found in three patients
(Tiffeneau indexo 70%). Treatment modalities applied for
LC are shown in Table 3. All patients had diffuse interstitial
lung lesions on chest imaging (CXR, chest computed
tomography). Comparing these lesions in the group of
patients with and those without LC, no difference
was found in terms of extension. Most of them had CT
features consistent with non-specific interstitial pneumonia
(NSIP).
Of the three patients who were operated, two submitted
to pneumonectomy, and one to lobectomy. With regard to
their LC staging, one patient presented with T2N0M0 stage
and two patients with T1N1M0. Adjuvant chemotherapy was
applied in all of them. Palliative radiotherapy was applied in
two patients with brain metastases.
Interestingly, seven patients were active smokers (six
patients with RA and one with DM). Significant difference
was found in association of LC and smoking in RA when
compared to patients with other CTD types (p ¼ 0.03).
Seven patients were former smokers. One RA patient-former
smoker had a smoking history of less than 10 pack-years,
while six others (86%) used to smoke more than 10 pack-
years. Patients’ median survival was 5 (range 0–96) months.
Figure 1 shows the survival of patients from the time they
were diagnosed with LC.Survival (months)
Mean 16.08
Median 5
Range 1–96
Abbreviations: NSCLC, non-small cell lung cancer; SCLC,
small-cell lung cancer.Discussion
In this case series of 24 patients with LC and CTD we found
that the most frequent histology is by far NSCLC (20/24,
83.3%) with the great majority of them (13/20, 65%) had
adenocarcinoma. SCLC consisted of 16.7% (4/24) which is
similar to the usual 20% reported in LC patients without CTD.
Also, despite the fact that LC more frequently occurs inTable 2 Lung cancer histology and stage in 24 patients
with connective tissue disease (CTD).
Type of
CTD
NSCLC-n (%) SCLC-n (%)
Adenocar-
cinoma
Squamous cell
carcinoma
DM 1
RA 3 (50) 2 (33) 1 (17)
SLE 3 (50) 1(17) 2 (33)
SSc 7 (64) 3 (27) 1 (9)
Total 13 (51.2%) 7 (29.2%) 4 (16.7%)
AJCC NSCLC stage
I 1 (4)
II 2 (8)
III 1 (4)
IV 20 (83)
Abbreviations: DM, dermatomyositis; RA, rheumatoid arthri-
tis; SLE, systemic lupus erythematosus; SSc, systemic
sclerosis, AJCC, American Joint Committee on Cancer.
Figure 1 Kaplan–Meier estimates of overall survival in patients
with lung cancer and connective tissue disease.male than in female, the vast majority were female (23/24).
Apart from the previous epidemiological evidence that some
CTDs are more frequent in women and only CTD pleuro-
pulmonary complications are more frequent in men, it
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Clinical features of lung cancer in patients with connective tissue diseases 623seems that female patients with CTD tend to develop more
frequently LC.19
The most intriguing feature of the patient population is
that of 24 LC patients 10 appear to be non-smokers. This
needs further investigation in carefully designed studies.
Speculations for independent carcinogenesis have been
discussed.1,2
None of our patients had bronchioloalveolar LC,
although others found it to be the most frequent
LC in CTD.16–18 The majority of our patients with adeno-
carcinoma had SSc. In early 1980s some studies have
shown the coexistence of LC and SSc,7 and later a population
based cohort study concluded that SSc, whether diffuse or
limited form, is associated with a similarly increased risk
of LC.3
It is difficult to precisely estimate the possible increased
risk of malignancy in CTD patients because of the rarity of
these diseases and therefore the small number of patients
available for study.20
It is known that the majority of patients with CTD have
underlying pathology consistent with NSIP, which has better
prognosis than that of usual interstitial pneumonia
(UIP).21,22 Due to retrospective nature of this work and the
number of patients, we did not find any differences taking
into account the pattern of interstitial pneumonia and the
survival of patients.
It should be noted that the majority of patients presented
at an advanced stage of LC with 87% having stage III or IV
disease. This stresses the necessity of making efforts for
earlier recognition of LC in patients with CTD with regular
follow-up, including chest imaging.
Older age and presence of fibrous lung changes are known
to carry higher risk for occurrence of LC.23,24 During the
course of CTD all of our patients were treated either with
systemic glucocorticoids or with immunosuppressive drugs
like methotrexate and cyclophosphamide. Opinions whether
a long term use of some immunosuppressive drugs leads to a
more frequent occurrence of LC in patients with CTD are
divided.25 Hilli et al. have shown that immunosuppressive
drugs do not play any significant role for LC development in
patients with SSc.3 We found a higher number of LC
in patients with limited form of SSc, where cytotoxic
drugs like cyclophosphamide were not administered, com-
paring to diffuse form of SSc (eight and three patients,
respectively).
There are studies that suggest a rapid progression of
cancer and a reduction of surviving in those operated for
LC.23,24 Only 3/24 of our CTD patients underwent surgery for
LC and the average follow-up time after surgery at present is
8, 12, and 23 months, respectively.
Current investigations in oncogenesis and stimulation of
fibrogenous processes will contribute to our better under-
standing of the pathogenesis of LC and CTD.1 Thus, the
relationship that exists between them remains a challenge
for further investigations that could make earlier effective
therapy, better survival, and, hopefully, primary prevention.
Furthermore, none of our patients has been treated with the
newer biological agents, which have been reported to
develop pulmonary fibrosis.26
In conclusion, patients with CTD, irrespective of
non-smoking, are likely to develop LC and should be
followed up regularly for early cancer detection andtreatment. Since the diagnosis is late, the prognosis is
dismal, probably due to the presence of diffuse pulmo-
nary lung fibrosis in most cases. Further prospective,
multicenter studies with properly applied diagnostic
tests for early diagnosis are warranted to further clarify
the exact incidence, course, and best management of these
patients.Conflicts of interest
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